1
|
Iacone A, Dragani A, Angelini A, Accorsi P, Fioritoni G, D'Antonio D, Torlontano G. Early Hematopoietic Reconstitution after Autologous Transplantation with Blood-Derived Stem Cells in a Patient with Advanced Lymphoma. Int J Artif Organs 2018. [DOI: 10.1177/039139888901200609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A 30-year-old man with advanced non-Hodgkin lymphoma underwent repeated leukaphereses for harvesting blood-derived hemopoietic stem cells. Collection was started 8-10 days after the end of L-VAMP therapy (3 cycles). Nine procedures were performed and a total of 65.4× 109 mononuclear cells (0.87× 109/Kg) were collected, processed, cryopreserved and stored in liquid nitrogen. The yields of CFU-GM, BFU-E and CFU-GEMM were respectively 964× 104 (12.4× 104/Kg), 249× 104 (3.2× 104/Kg) and 798× 104 (10.4× 104). The patient received a myeloablative regimen consisting of fractionated total body irradiation (1200 cGy) and cyclophosphamide (120 mg/kg) followed by infusion of his own thawed cells. Early trilineage hematopoietic recovery was first observed on day +8; 1× 109/l WBC were reached on day + 11, 0.5× 109/l PMN on day + 13 and 50× 109/l platelets on day + 11. Course was uneventful and the patient was discharged from hospital on day + 21. Eight months after transplant the patient is in continuous unmaintained complete remission with normal blood cell counts. This reports suggests that complete and sustained engraftment can be achieved with peripheral stem cells recruited after “soft” chemotherapy.
Collapse
Affiliation(s)
- A. Iacone
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - A. Dragani
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - A. Angelini
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - P. Accorsi
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - G. Fioritoni
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - D. D'Antonio
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| | - G. Torlontano
- Chair of Hematology, University of Chieti, Civil Hospital of Pescara - Italy
- Division of Hematology and Blood Bank, Civil Hospital of Pescara - Italy
| |
Collapse
|
2
|
Takaue Y. Peripheral Blood Stem Cell Autografts in Children with Acute Lymphoblastic Leukemia and Lymphoma: Updated Experience. Leuk Lymphoma 2009; 3:241-56. [DOI: 10.3109/10428199109107912] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
3
|
|
4
|
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol 2002; 118:1048-54. [PMID: 12199784 DOI: 10.1046/j.1365-2141.2002.03765.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In attempting to restore the chronic phase (CP) of chronic myelogenous leukaemia (CML), the Swedish CML group utilized an intensive chemotherapy protocol for 83 patients (aged 16-79 years) in accelerated (AP, n = 22) or blastic phase (BC, n = 61). Most patients received a combination of mitoxantrone (12 mg/m2/d) and etoposide (100 mg/m2/d) together with cytosine arabinoside (1 g/m2 b.i.d) for 4 d. Overall, 39 patients (47%) achieved a second CP (CP2)/partial remission (PR). Responding patients < 65 years were eligible for ablative chemotherapy followed by an allogeneic (SCT) or a double autologous stem cell transplant (ASCT). Seventeen of 34 responders < 65 years failed to proceed to transplantation as a result of early disease progression (n = 15) or disease-related complications (n = 2). The remaining 17 patients underwent SCT (n = 9; including four unrelated donor SCT) or ASCT (n = 8). Only one of the eight ASCT patients had a second ASCT; the remaining seven failed because of progression (n = 5) or hypoplasia (n = 2). The median duration of CP2/PR was 6 months (range 1-72 months). Five patients achieved a longer CP2/PR than CP1. The 1 year survival was 70% for SCT/ASCT patients (median survival 21 months), 50% for responding patients overall, but only 7% for non-responders (P < 0.001). Three SCT/ASCT patients are long-term survivors (65+, 66+ and 73+ months). In conclusion, approximately half of the patients achieved a CP2/PR after intensive chemotherapy, with a clear survival advantage for responders vs non-responders. Subsequent SCT/ASCT was feasible for half of the responders (< 65 years), and one individual underwent double ASCT. Novel therapeutic options for CML patients in AP/BP are needed.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Blast Crisis
- Combined Modality Therapy
- Cytarabine/administration & dosage
- Etoposide/administration & dosage
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery
- Male
- Middle Aged
- Mitoxantrone/administration & dosage
- Prognosis
- Remission Induction
- Statistics, Nonparametric
- Stem Cell Transplantation
- Survival Rate
Collapse
Affiliation(s)
- Ulla Axdorph
- Division of Haematology, Department of Medicine, Karolinska Hospital and Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R, Henslee-Downey PJ, Akard LP. Peripheral blood progenitor cell transplantation. THERAPEUTIC APHERESIS : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR APHERESIS AND THE JAPANESE SOCIETY FOR APHERESIS 2002; 6:5-14. [PMID: 11886571 DOI: 10.1046/j.1526-0968.2002.00392.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Peripheral blood progenitor cells (PBPCs) have become increasingly popular over the last 15 years as the source of hematopoietic stem cells for transplantation. In the early 1990s, PBPCs replaced bone marrow (BM) as the preferred source of autologous stem cells, and recently the same phenomenon is seen in the allogeneic setting. Under steady-state conditions, the concentration of PBPCs (as defined by CFU-GM and/or CD34+ cells) is very low, and techniques were developed to increase markedly this concentration. Such mobilization techniques include daily injections of filgrastim (G-CSF) or a combination of chemotherapy and growth factors. Leukapheresis procedures allow the collection of large numbers of circulating white blood cells (and PBPCs). One or two leukapheresis procedures are often sufficient to obtain the minimum number of CD34+ cells considered necessary for prompt and consistent engraftment (i.e., 2.5-5.0 x 10(6)/kg). As compared to BM, autologous transplants with PBPCs lead to faster hematologic recovery and have few, if any, disadvantages. In the allogeneic arena, PBPCs also result in faster engraftment, but at a somewhat higher cost of chronic graft-versus-host disease (GvHD). This may be a double-edged sword leading to both increased graft-versus-tumor effects and increased morbidity. The rapid advances in the study of hematopoietic, and even earlier, stem cells will continue to shape the future of PBPC transplantation.
Collapse
Affiliation(s)
- Jan Jansen
- Indiana Blood and Marrow Transplantation, Indianapolis, Indiana 46237, USA.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
For most chronic myeloid leukaemia (CML) patients the option of a potentially 'curative' allogeneic stem cell transplant is not available because of age or lack of donor. Interferon alpha appears to extend survival when used in the chronic phase of the disease but probably does not produce long-term disease-free survivors. Autografting is being actively explored as a therapeutic option which may improve on the survival data seen with interferon and numerous different autografting methodologies are being investigated. While it seems reasonable to hope that a suitably robust and safe approach to autografting may improve survival it is unlikely with current technology that long-term disease-free survival will be achieved. To date no compelling trial data are available to confirm the efficacy of autografting but large prospective randomized studies are underway to investigate whether autografting can indeed extend survival for CML patients who do not have the option of an allograft.
Collapse
MESH Headings
- Disease-Free Survival
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Randomized Controlled Trials as Topic
- Transplantation, Autologous
- Treatment Outcome
Collapse
Affiliation(s)
- S G O'Brien
- Department of Haematology, University of Wales College of Medicine, Cardiff, UK
| |
Collapse
|
7
|
|
8
|
Affiliation(s)
- W Bensinger
- Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
| |
Collapse
|
9
|
Tringali S, Santoro A, Scimé R, Vasta S, Pampinella M, Marino MA, Majolino I. High-dose cyclophosphamide for mobilization of circulating stem cells in chronic myeloid leukemia. Eur J Haematol 1994; 53:1-5. [PMID: 7914874 DOI: 10.1111/j.1600-0609.1994.tb00170.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Experimental and clinical data suggest that Ph-negative myeloid progenitor cells are present, albeit suppressed, in the bone marrow of chronic myeloid leukemia (CML) patients. These residual Ph-negative cells might, in certain circumstances, regain their proliferative advantage over the leukemic Ph-positive clone. Treating CML patients with intensive chemotherapy might allow the harvest, in the early phase of recovery, of Ph-negative stem cells to be used as graft after myeloablative regimen. In our study, 6 CML patients were admitted to a program of autograft with circulating stem cells (CSC) collected after high-dose (5 or 7 g/m2) cyclophosphamide (HD-CY) mobilization. All were autografted, using busulphan 16 mg/kg and melphalan 60 mg/m2. As graft, 4 patients received CSC only, while 2 patients were also given bone marrow, as their peripheral blood CFU-GM yield was unsatisfactory. Two previously alpha-IFN-responding patients showed a slow hematologic recovery, but achieved a marked and further reduction of their Ph-positive metaphases post-graft. Moreover, in one of them, cytogenetic analyses performed on apheresis product showed a more pronounced reduction of his Ph-positive metaphases, as compared to bone marrow samples, suggesting a potential purging effect of the mobilization procedure.
Collapse
Affiliation(s)
- S Tringali
- Department of Hematology and Bone Marrow Transplant Unit, Ospedale Cervello, Palermo, Italy
| | | | | | | | | | | | | |
Collapse
|
10
|
Preisler HD, Raza A, Baccarani M. Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. Leuk Lymphoma 1993; 11 Suppl 1:303-6. [PMID: 7504547 DOI: 10.3109/10428199309047903] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
This presentation discusses the role that proliferative advantage plays in making both the chronic and blastic phases of CML resistant to therapy. A case is made for the addition of "regrowth" inhibitors between courses of chemotherapy as a means of increasing the efficacy of therapy by suppressing or reducing the proliferative advantage that the target cells enjoy over those cells which one would like to repopulate the hematopoietic system.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Antineoplastic Agents/pharmacology
- Antineoplastic Agents/therapeutic use
- Blast Crisis/drug therapy
- Blast Crisis/pathology
- Carrier Proteins/metabolism
- Cell Division/drug effects
- Drug Resistance
- Drug Synergism
- Gene Expression Regulation, Leukemic/drug effects
- Genes, myc/drug effects
- Humans
- Immunologic Factors/pharmacology
- Immunologic Factors/therapeutic use
- Interferons/pharmacology
- Interferons/therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myeloid, Chronic-Phase/drug therapy
- Leukemia, Myeloid, Chronic-Phase/pathology
- Membrane Glycoproteins/metabolism
- Neoplasm Proteins/metabolism
- Neoplastic Stem Cells/drug effects
- Neoplastic Stem Cells/pathology
- Selection, Genetic
- Treatment Failure
- Tretinoin/pharmacology
- Tretinoin/therapeutic use
Collapse
Affiliation(s)
- H D Preisler
- Division of Hematology/Oncology, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL 60612
| | | | | |
Collapse
|
11
|
Shimizu E, Mukai JN, Takaue Y, Ogura T. Circulating hematopoietic progenitors in patients with primary lung cancer. Jpn J Cancer Res 1990; 81:1293-9. [PMID: 2125998 PMCID: PMC5918003 DOI: 10.1111/j.1349-7006.1990.tb02693.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The levels of circulating hematopoietic progenitors were measured in 28 patients with primary lung cancer. The average numbers of progenitors per milliliter of blood were 33 (range 0-360) for colony-forming unit-granulocyte macrophage (CFU-GM), 23 (range 0-140) for burst-forming unit-erythrocyte (BFU-E), and 4 (range 0-50) for colony-forming unit-mixed lineages (CFU-mix). No significant influence of age, sex, histological type, or clinical stage of the tumor on the progenitor levels was detected. After cytoreductive chemotherapy of the patients by treatment with cisplatin plus etoposide, the cells showed 6- to 50-fold rebound overshoots, but no rebound was observed after treatment with cisplatin alone, cisplatin plus mitomycin C or cisplatin plus vindesine plus mitomycin C, or in 4 of 5 patients treated with cyclophosphamide plus adriamycin plus vincristine. Peripheral blood hematopoietic progenitors should be useful as an alternative source of stem cells for lung cancer patients treated with marrow ablative chemotherapy.
Collapse
Affiliation(s)
- E Shimizu
- Third Department of Internal Medicine, University of Tokushima School of Medicine
| | | | | | | |
Collapse
|
12
|
|
13
|
Law P, Dooley DC, Alsop P, Smith DM, Landmark JD, Meryman HT. Density gradient isolation of peripheral blood mononuclear cells using a blood cell processor. Transfusion 1988; 28:145-50. [PMID: 3354042 DOI: 10.1046/j.1537-2995.1988.28288179019.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Large numbers of mononuclear cells (MNC) are needed for hematologic reconstitution using peripheral blood stem cells. The possibility of isolating those cells by discontinuous Ficoll-diatrizoate density gradient centrifugation in two blood cell processors (the Haemonetics V50 [V50] and the Cobe 2991 [2991]) were examined. Buffy coats from peripheral blood containing 6.23 X 10(8) MNC were separated in the V50, resulting in a recovery of 75 percent. The purity of the cells, defined as the percentage of lymphocytes and monocytes among all leukocytes, was 95 percent. With larger cell loads (3 to 7 X 10(9) MNC), the yield was higher in the V50 than in the Cobe 2991 (92 versus 75%). After separation in the V50 or the 2991, the cloning efficiencies of hematopoietic progenitor cells (CFU-GM and BFUe) were not different from those of cells isolated on 5 ml Ficoll-diatrizoate gradients in centrifuge tubes. Both leukapheresis and MNC separation can be carried out with the same bowl and tubing set in the V50. With that approach, an average of 6 X 10(9) MNC were processed in 16 experiments. An average recovery of 82 percent with 95 percent purity was achieved. The authors conclude that, in terms of simplicity of operation, cost effectiveness, and maintenance of sterility, the V50 may be better suited than the 2991 for the purification of MNC from peripheral blood.
Collapse
Affiliation(s)
- P Law
- American Red Cross, Biomedical Research and Development Laboratory, Rockville, Maryland
| | | | | | | | | | | |
Collapse
|
14
|
Körbling M, Martin H. Transplantation of hemapheresis-derived hemopoietic stem cells: A new concept in the treatment of patients with malignant lymphohemopoietic disorders. ACTA ACUST UNITED AC 1988. [DOI: 10.1016/0278-6222(88)90044-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Abstract
Transplantation of haemopoietic stem cells provides a means whereby patients with malignant disease may be treated with increased doses of chemotherapy or chemoradiotherapy. Until recently, the bone marrow has been the sole source of these cells. However, haemopoietic progenitors can also be demonstrated in the blood and it has been known for more than twenty years that peripheral blood mononuclear cells are capable of repopulating the marrow in animals. This phenomenon has recently been reproduced in man. The use of peripheral blood rather than bone marrow for autologous stem cell rescue may have advantages in terms of ready access, availability in patients with compromised pelvic bone marrows, a lower risk of tumour contamination and more rapid granulocyte and immune recovery. However, clinical experience with peripheral blood stem cell autografting is still very small. This review discusses the characteristics of circulating stem cells, the methods by which they can be collected and stored and the information which has come from recent studies of their transplantation in man.
Collapse
|
16
|
Douay L, Lopez M, Gorin NC, Nauman A, Giarratana MC, Laporte JP, Stachowiak J, Salmon C, Duhamel G. Failure of bone marrow cryopreservation in chronic granulocytic leukemia: relation to excessive granulo-macrophagic progenitor pool. INTERNATIONAL JOURNAL OF CELL CLONING 1986; 4:250-62. [PMID: 2875118 DOI: 10.1002/stem.5530040403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Autologous bone marrow transplantation (ABMT) in chronic granulocytic leukemia (CGL) aims at reversing the acute or acceleration phases by injection of stem cells collected during the chronic phase. This study was designed to explain an unusual rate of delayed engraftment (50%) in our experience of ABMT in CGL patients. We investigated all the factors possibly responsible for abnormal perpetuation of aplasia following infusion of cryopreserved marrow stem cells. The study of CFU-gm recovery in 41 bags of frozen marrow from 25 patients revealed an overall deficiency with a mean CFU-gm recovery of 55 +/- 38% in CGL patients versus 73 +/- 15% in the control group (p less than 0.001). Our data also showed an inverse linear relation (r = -0.40, p less than 0.05) between CFU-gm concentration and recovery after freezing. A good CFU-gm recovery (greater than or equal to = 50%) was observed in 70% of cases when the concentration was less than 3700 CFU-gm/ml as compared to 30% of cases when the concentration was over 3700 CFU-gm/ml (p less than 0.001). The lack of improvement by diluting rich CFU-gm marrows to reduce CFU-gm concentration/ml, as well as the absence of relationship between CFU-gm recovery after freezing and nucleated cells concentration, suggest a particular fragility of CGL stem cells to freezing, probably related to their excessive amplification. At the present time, we strongly recommend that the highest possible dose of progenitor cells be cryopreserved, preferably at a low concentration, in patients with CGL, and particular attention devoted to the freezing procedure in each individual patient, with numerous appropriate efficiency tests.
Collapse
|
17
|
Marcus RE, Goldman JM. Autografting in chronic granulocytic leukaemia. CLINICS IN HAEMATOLOGY 1986; 15:235-47. [PMID: 3516491 DOI: 10.1016/s0308-2261(86)80014-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
18
|
Gorin NC. Collection, manipulation and freezing of haemopoietic stem cells. CLINICS IN HAEMATOLOGY 1986; 15:19-48. [PMID: 2870831 DOI: 10.1016/s0308-2261(86)80004-2] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
19
|
de Witte T, Raymakers R, de Pauw B, Haanen C. Repetitive cycles of cytoreductive therapy followed by stem cell autografting for nonlymphoblastic transformation of chronic granulocytic leukaemia. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1985; 35:558-63. [PMID: 2418493 DOI: 10.1111/j.1600-0609.1985.tb02828.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Treatment of nonlymphoblastic transformation of chronic granulocytic leukaemia (CGL) by marrow ablative chemotherapy, followed by autologous stem cell reinfusion, induced a 2nd chronic phase with a median duration of 5.5 months at the cost of high morbidity and mortality. One course of intensive cytoreductive chemotherapy, similar to a remission induction course in acute nonlymphoblastic leukaemia (ANLL), followed by a buffy coat reinfusion, induced a short-lived 2nd chronic phase in 4 out of 9 patients. Two successive courses, each followed by an autologous stem cell reinfusion, induced a new chronic phase in 4 out of 5 consecutive patients. Multiple intensive chemotherapy courses, followed by autologous stem cell rescue, offer an effective palliative treatment of nonlymphoblastic transformation of CGL with a relatively low morbidity due to the treatment itself.
Collapse
|
20
|
Karp DD, Parker LM, Binder N, Tantravahi R, Smith BR, Ervin TJ, Canellos GP. Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol 1985; 18:243-9. [PMID: 2858155 DOI: 10.1002/ajh.2830180304] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Seven nonsplenectomized patients with blastic CGL have received high dose BCNU chemotherapy followed by cryopreserved peripheral blood stem cells (PBSC). The PBSC obtained at diagnosis were stored in the vapor phase of liquid nitrogen in 10% dimethyl sulfoxide for 11-46 months prior to use. Patients received 2.9 X 10(8) (1.9-7.8) thawed washed mononuclear cells/kg over 30 minutes with minimal morbidity. One patient was not rendered pancytopenic and died with blastic leukemia at 4 months. One patient, previously treated with daily busulfan, died of progressive hepatic failure 2 months after high dose BCNU. Restoration of the chronic phase of CGL was observed in the remaining five patients. Peripheral blood counts returned to normal ranges after a median of 19 days. Median survival for all patients is 11 months. Cytogenetic studies revealed elimination of acquired aneuploid cell lines in four of seven patients with persistence of Ph1. We conclude that: 1) frozen PBSC retain their viability for up to 4 years after cryopreservation and 2) the use of autologous PBSC following ablative chemotherapy may be associated with both symptomatic and karyotypic improvement in patients with blastic CGL.
Collapse
|
21
|
Abstract
The prognosis of patients with CML has improved little in the past 50 years. The relatively benign chronic phase invariably deteriorates to a refractory and rapidly fatal terminal phase. This terminal stage has been found to have two major subtypes as defined by morphologic, cytochemical, immunologic, and enzymatic criteria--myeloblastoid and lymphoblastoid. Aggressive combination chemotherapy has achieved minimal improvement in survival once the terminal phase has begun, perhaps because only Ph1-positive stem cells remain to repopulate the marrow at this stage. Bone marrow transplantation has also been unsuccessful as therapy for the terminal phase, possibly because the patients are too debilitated to tolerate transplantation once the terminal phase has begun. Combination chemotherapy has been applied in an effort to eliminate the Ph1 chromosome-containing clone during the chronic phase. This goal has not yet been consistently achieved. Chemotherapy has also not been able to delay the onset of the terminal phase nor to prolong survival. Even in those patients in whom the Ph1 chromosome-containing clone has been eliminated, relapse to the chronic phase with return of the Ph1 chromosome has generally occurred within a brief period of time. Bone marrow transplantation during the chronic phase may hold the promise of true cure for CML, with permanent elimination of the malignant clone. However, the chronic phase can be unpredictably long and patients in the chronic phase often have few, if any symptoms. Therefore, there has been a reluctance to employ drastic therapy during the chronic phase. Techniques to predict the transformation to the terminal phase prior to overt morphologic or clinical conversion are now being developed. It may be possible in the future to attempt HLA-matched sibling donor bone marrow transplantation at the earliest signs of transformation from the chronic to the terminal phase. In this manner, optimal survival might be achieved by allowing patients to be maintained in the chronic phase for as long as possible prior to the initiation of aggressive therapy. Until this is routinely possible, continued research designed to improve the therapy of the terminal phase must be pursued. These attempts are likely to include the development and evaluation of new chemotherapeutic agents, novel methods of administration of existing drugs to better exploit their pharmacokinetics (for example, continuous infusion), and the utilization of newly described treatment approaches (such as the use of "differentiating" agents in an attempt to prevent progression to blastic transformation).(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
22
|
Haines ME, Goldman JM, Worsley AM, McCarthy DM, Wyatt SE, Dowding C, Kearney L, Th'ng KH, Wareham NJ, Pollock A. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol 1984; 58:711-21. [PMID: 6151399 DOI: 10.1111/j.1365-2141.1984.tb06118.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Between June 1977 and July 1983 51 patients with Ph1-positive chronic granulocytic leukaemia (CGL) in transformation were treated either by chemotherapy or by chemoradiotherapy followed by autografting with haemopoietic stem cells collected from their peripheral blood at the time of diagnosis. Forty-eight patients were restored to a second chronic phase. The median duration of survival after autografting was 26 weeks (range 2-152 weeks). Twenty-one patients with relatively long durations of second chronic phase were treated again by autografting as consolidation or when transformation recurred; this selected group of patients survived longer than the 30 patients treated by autografting only once (medians 52 v. 13 weeks respectively, P less than 0.01). There was no significant influence of the patients' age, splenectomy status, type of transformation, treatment pre-autograft or number of nucleated cells autografted on the duration of survival. Three patients treated in myeloid blastic transformation were restored to partially Ph1-negative haemopoiesis. We conclude that this approach to the management of CGL in transformation can offer benefit for a minority of patients and that further chemotherapy and autografting for patients still in second chronic phase may be valuable.
Collapse
|
23
|
Gibson J, Joshua DE, Collis D, Kronenberg H. Chronic myeloid leukaemia presenting as femoral head necrosis. SCANDINAVIAN JOURNAL OF HAEMATOLOGY 1984; 32:376-8. [PMID: 6585928 DOI: 10.1111/j.1600-0609.1984.tb00691.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
A 17-year-old male whose initial presentation of chronic myeloid leukaemia (CML) was necrosis of the right femoral head is reported. This is the first case report to our knowledge of CML presenting with such a lesion and is of further interest in that almost all reported cases of destructive bony lesions in this disease have been associated with blast transformation. Our patient in contrast has remained in stable chronic phase for over 30 months.
Collapse
|
24
|
Mehta AB, Goldman JM, Kohner E. Hyperleucocytic retinopathy in chronic granulocytic leukaemia: the role of intensive leucapheresis. Br J Haematol 1984; 56:661-7. [PMID: 6585220 DOI: 10.1111/j.1365-2141.1984.tb02190.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We describe three patients with chronic granulocytic leukaemia who developed impaired visual acuity in association with high leucocyte counts. Two of the patients were in the chronic phase of their disease and the third developed visual symptoms at the time of blastic transformation. Fundoscopy showed retinal haemorrhages and exudates and a vascular picture consistent with hyperviscosity. We propose the term 'hyperleucocytic retinopathy' for these appearances. Two of the patients derived rapid benefit following leucapheresis and the visual acuity of the third patient improved following treatment with cytotoxic drugs.
Collapse
|
25
|
Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell JH. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect 1984; 5:83-91. [PMID: 6202753 DOI: 10.1016/0195-6701(84)90105-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Forty-eight neutropenic patients with acute leukaemia were randomly allocated to receive, as antifungal prophylaxis, either ketoconazole, 400 mg once daily (K), or amphotericin B tablets and lozenges (A), or both ketoconazole and amphotericin B together (K + A). Antifungal prophylaxis was considered to have failed if (1) there was evidence of increasing colonization of the oropharynx or faeces with Candida spp. or other yeasts, or (2) if systemic antifungal therapy was begun empirically. Prophylaxis failed in nine of 17 patients given K, in four of 19 given A, and in four of 12 given K + A. The differences between the three regimens were not statistically significant, neither was there any significant difference in the mean duration of neutropenia before prophylaxis failed. The absorption of ketoconazole was impaired when patients were neutropenic. We conclude that ketoconazole was neither more nor less effective than amphotericin B in the prevention of yeast colonization in neutropenic patients.
Collapse
|
26
|
Minchinton RM, Waters AH, Malpas JS, Starke I, Kendra JR, Barrett AJ. Platelet- and granulocyte-specific antibodies after allogeneic and autologous bone marrow grafts. Vox Sang 1984; 46:125-35. [PMID: 6369779 DOI: 10.1111/j.1423-0410.1984.tb00064.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
After bone marrow grafting, severe unexplained thrombocytopenia and granulocytopenia may complicate the post-graft recovery of the patient. The present study has shown the presence of antibodies to platelets and granulocytes of donor origin in recipients of both allogeneic and autologous bone marrow grafts. In the case of autografts, such antibodies are by definition autoantibodies, and similar antibodies after allografting may also have an autoimmune origin. It is likely that this is the result of transient immune system imbalance, common to both allo- and autografts, in the early post-graft period. The extent to which these antibodies affect the peripheral counts probably depends on the ability of the engrafted marrow to compensate for the rate of antibody-mediated cell destruction.
Collapse
|
27
|
Starke ID, de Beer FC, Donnelly JP, Catovsky D, Goldman JM, Galton DA, Pepys MB. Serum C-reactive protein levels in the management of infection in acute leukaemia. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1984; 20:319-25. [PMID: 6584311 DOI: 10.1016/0277-5379(84)90076-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
C-reactive protein (CRP) was measured serially in 29 patients with acute leukaemia. Sixty-four febrile episodes (greater than or equal to 38 degrees C) occurred during 37 periods of neutropenia (less than 0.5 X 10(9)/l). In all of 41 microbiologically or clinically documented infections the maximum CRP level exceeded 30 mg/l, and in 25 it was greater than 100 mg/l. In no case in which the CRP level remained below 30 mg/l for 48 hr after the onset of fever was any clinical or microbiological evidence of infection obtained. The CRP level during documented infection began to fall 24-48 hr after appropriate treatment was begun. A CRP level above 30 mg/l in neutropenic patients was associated with early recurrence of fever if systemic antibiotics were discontinued. Graft-vs-host disease, without infection, did not result in high levels of CRP.
Collapse
|
28
|
Abstract
Bone marrow collected from all species including man contains specific cells, putative pluripotential stem cells, capable of reestablishing hemopoiesis in a syngeneic or genetically identical member of the same species which has been treated with whole body irradiation. The question of whether similar pluripotential stem cells are present in the circulation in all animals is not yet resolved. In mice, reconstitution of hemopoiesis can be achieved by transfusion of peripheral blood cells only. The same result can be obtained in dogs and probably in baboons. In dogs, experiments with fresh and cryopreserved blood mononuclear cells have confirmed a dose-response relationship--below a certain number of mononuclear cells failure of hemopoietic reconstitution can be predicted. In man, isolated anecdotal case reports suggest that pluripotential stem cells in the circulation may or may not be valuable in repopulating a bone marrow defective as a result of primary disease or following chemotherapy. Indirect evidence from in vitro culture of circulating myeloid progenitor cells suggests but does not prove that pluripotential stem cells circulate in normal man. Pluripotential stem cell numbers are probably greatly increased in the circulation in patients with chronic granulocytic leukemia: such cells can be collected, cryopreserved, and used at a later date as "bone marrow autografts". Whether circulating stem cells can be collected and used in an analogous manner for patients with other leukemias or other neoplasms is not yet established.
Collapse
|
29
|
|
30
|
Vogler WR, Winton EF, James S, O'Neill S, Granade S, Mallard G. Autologous marrow transplantation after karyotypic conversion to normal in blastic phase of chronic myelocytic leukemia. Am J Med 1983; 75:1080-4. [PMID: 6359875 DOI: 10.1016/0002-9343(83)90893-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
A patient with blastic transformation of Philadelphia chromosome-positive chronic myelocytic leukemia was treated with acridinyl anisidide, which resulted in conversion to a normal karyotype. At that time, bone marrow was harvested and cryopreserved. After relapse, the patient was treated with cyclophosphamide and fractionated total body irradiation followed by autologous marrow transplantation. Serial karyotypes and blood counts, determined up to 14 months after transplantation, remained normal.
Collapse
|
31
|
Goldman JM, Baughan A. Application of bone marrow transplantation in chronic granulocytic leukaemia. CLINICS IN HAEMATOLOGY 1983; 12:739-53. [PMID: 6357580 DOI: 10.1016/s0308-2261(83)80008-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
MESH Headings
- Adolescent
- Adult
- Bone Marrow Transplantation
- Cell Transformation, Neoplastic/pathology
- Child
- Child, Preschool
- Chromosomes, Human, 21-22 and Y
- Female
- Humans
- Karyotyping
- Leukemia, Myeloid/genetics
- Leukemia, Myeloid/pathology
- Leukemia, Myeloid/therapy
- Male
- Middle Aged
- Recurrence
- Spleen/pathology
- Splenectomy
- Transplantation, Autologous
- Transplantation, Homologous
- Transplantation, Isogeneic/methods
Collapse
|
32
|
Muretto P, Izzi T, Grianti C, Moretti L. Histomorphologic Study of Bone Marrow in Acute Leukemia following Chemotherapy and Autologous Bone Marrow Transplantation. TUMORI JOURNAL 1983; 69:239-48. [PMID: 6346621 DOI: 10.1177/030089168306900312] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Twenty-six patients with acute myeloid leukemia, acute lymphoid leukemia and chronic granulocytic leukemia in blast crisis were studied by means of multiple biopsies during a polychemotherapeutic or autologous bone marrow transplant protocol. Following chemotherapy, 3 main phases were observed: leukemic cellular depletion, stromal bone marrow reconstruction, and bone marrow hemopoietic restoration. Following intensive chemotherapy (in 2 patients after cyclophosphamide and total body irradiation) and autologous bone marrow transplantation, the 3 phases appeared to be shorter. A focal or diffuse increase in marrow fibrosis was a common finding in leukemia. An effective antileukemic therapy resulted in a decrease in fibrosis, whereas in some cases a further increase was a precocious sign of leukemia relapse.
Collapse
MESH Headings
- Adolescent
- Adult
- Antineoplastic Agents/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols
- Biopsy
- Bone Marrow/pathology
- Bone Marrow Transplantation
- Child
- Cyclophosphamide/administration & dosage
- Cytarabine/administration & dosage
- Daunorubicin/administration & dosage
- Doxorubicin/administration & dosage
- Drug Therapy, Combination
- Female
- Humans
- Leukemia, Lymphoid/pathology
- Leukemia, Lymphoid/therapy
- Leukemia, Myeloid/pathology
- Leukemia, Myeloid/therapy
- Leukemia, Myeloid, Acute/pathology
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Prednisolone/administration & dosage
- Thioguanine/administration & dosage
- Time Factors
- Transplantation, Autologous
- Vincristine/administration & dosage
- Whole-Body Irradiation
Collapse
|
33
|
Hurd DD. The chronic leukemias. Clinical picture, diagnosis, and management. Postgrad Med 1983; 73:217-9, 222-7, 231. [PMID: 6573652 DOI: 10.1080/00325481.1983.11697840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The chronic leukemias have an annual incidence in the United States of about 12,000 cases. The most common types are chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL). Less common are hairy cell leukemia (HCL) and prolymphocytic leukemia (PLL). All forms have an insidious onset and vague, non-specific presenting symptoms, eg, fatigue, malaise, night sweats, weight loss. Chemotherapy is the initial treatment for CML and CLL; splenectomy, splenic irradiation, and leukapheresis may also be helpful. Splenectomy is the preferred treatment for HCL. Until recently all chronic leukemias have been ultimately fatal, but the new approach of allogeneic bone marrow transplantation now used in some cases of CML may prove to be curative if done before the disease has progressed too far.
Collapse
|
34
|
Goolden AW, Goldman JM, Kam KC, Dunn PA, Baughan AS, McCarthy DM, Worsley AM, Gordon-Smith EC, Samson D, Catovsky D, Galton DA. Fractionation of whole body irradiation before bone marrow transplantation for patients with leukaemia. Br J Radiol 1983; 56:245-50. [PMID: 6338988 DOI: 10.1259/0007-1285-56-664-245] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Thirty patients in various stages of acute leukaemia or chronic granulocytic leukaemia (CGL) were treated with cytotoxic drugs followed by whole body irradiation (TBI) administered in 200 cGy fractions twice daily to a total of 1000 or 1200 cGy. The immediate toxicity of fractionated TBI administered in this way was negligible and patients required only minor premedication and little treatment subsequently for complications attributable to TBI. Fourteen (47%) patients have died, ten of the 12 transplanted with active disease, and four of the 18 subjected to transplantation in remission of acute leukaemia or in chronic phase of CGL. Though the duration of follow-up is still short, no patient in the latter group (follow-up of survivors ranging from six to 146 weeks) has yet relapsed with any evidence of recurrent leukaemia. We conclude that this method of fractionating TBI reduced toxicity for the patient without necessarily reducing its antileukaemic effect.
Collapse
|
35
|
Lasky LC. Collection, storage, and use of hematopoietic stem cells from peripheral blood. Hum Pathol 1983; 14:248-50. [PMID: 6339359 DOI: 10.1016/s0046-8177(83)80025-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Complete hematopoietic reconstitution using nonleukemic peripheral blood mononuclear cells has yet to be achieved in humans. Significant advances have been made in in vitro quantification of putative stem cells, in animal models of the reconstitutive process, and in the collection, processing, and storage techniques for stem cell preparations. These may eventually lead to use of hematopoietic stem cells from peripheral blood for both allogeneic and autologous bone marrow reconstitution in a variety of clinical situations.
Collapse
|
36
|
Islam A, Catovsky D, Goldman JM, Galton DA. Histological study of the bone marrow in chronic granulocytic leukaemia in blast transformation. II. Bone marrow fibre content before and after autografting. Histopathology 1981; 5:491-8. [PMID: 7026406 DOI: 10.1111/j.1365-2559.1981.tb01812.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A serial study of the extent of bone marrow (BM) fibrosis was carried out in 14 patients with chronic granulocytic leukaemia (CGL) in blast transformation (BT) who received intensive treatment followed by autografts to restore marrow haemopoiesis. Some degree of marrow fibrosis (MF) was identified in 13 of the 14 patients when blast transformation was diagnosed. A transient increase in the amount of marrow fibrosis was observed in most cases immediately following intensive chemoradiotherapy or chemotherapy alone but this had regressed by 4-6 weeks when chronic phase haemopoiesis was established in the marrow. The presence of marrow fibrosis when blast transformation was diagnosed did not appear to impair the effectiveness of the autograft.
Collapse
|